The Era of IL-23: Introduction of Tildrakizumab

Authors

  • Melinda Gooderham, MSc, MD, FRCPC Medical Director, SKin Health Investigator; Probity Medical Research Assistant Professor, Queen’s University

Abstract

Targeting the p19 subunit of interleukin (IL)-23 has been a major development in the management of plaque psoriasis because of the durable efficacy and safety of this mechanism of action. This supplement will review the pivotal data in the tildrakizumab development program: reSURFACE-1 and reSURFACE-2. Dr. Devani and Dr. Prajapati provide a comprehensive evidence-based review of the pivotal trials including the post-hoc analyses which review specific patient subpopulations, interruption/retreatment as well as a discussion of patient-level PASI score distributions across severities.

References

NA

Downloads

Published

2021-03-01

How to Cite

1.
Gooderham M. The Era of IL-23: Introduction of Tildrakizumab. Can Dermatol Today [Internet]. 2021 Mar. 1 [cited 2024 Nov. 21];2(s03):2. Available from: https://canadiandermatologytoday.com/article/view/2-s03-gooderham

Issue

Special Supplement, March 2021

Section

Articles

Most read articles by the same author(s)